Company Quick10K Filing
Leap Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$1.49 23 $34
10-Q 2019-09-30 Quarter: 2019-09-30
S-1 2019-07-31 Public Filing
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
8-K 2019-11-18 Other Events
8-K 2019-11-14 Earnings, Exhibits
8-K 2019-09-16 Regulation FD, Exhibits
8-K 2019-08-09 Earnings, Exhibits
8-K 2019-08-06 Other Events, Exhibits
8-K 2019-07-10 Enter Agreement, Sale of Shares, Other Events, Exhibits
8-K 2019-06-11 Shareholder Vote
8-K 2019-05-17 Other Events
8-K 2019-05-15 Earnings, Exhibits
8-K 2019-04-01 Earnings, Exhibits
8-K 2019-03-18 Other Events, Exhibits
8-K 2019-02-05 Other Events, Exhibits
8-K 2019-02-01 Enter Agreement, Exhibits
8-K 2019-02-01 Other Events, Exhibits
8-K 2019-01-31 Other Events, Exhibits
8-K 2019-01-24
8-K 2019-01-14 Other Events, Exhibits
8-K 2018-12-14 Other Events, Exhibits
8-K 2018-11-13 Enter Agreement, Exhibits
8-K 2018-10-21 Other Events, Exhibits
8-K 2018-09-07 Enter Agreement, Exhibits
8-K 2018-07-23 Other Events, Exhibits
8-K 2018-05-03 Shareholder Vote
8-K 2018-04-16 Other Events, Exhibits
8-K 2018-03-27 Other Events, Exhibits
8-K 2018-03-23 Enter Agreement, Exhibits
8-K 2018-03-22 Other Events, Exhibits
8-K 2018-03-14 Other Events, Exhibits
8-K 2018-01-12 Enter Agreement, Shareholder Rights, Shareholder Vote, Exhibits

Leap Therapeutics Financials

-

LPTX Metrics, Comps, Filings


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarter)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarter)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Assets Liabilities Revenue Gross Profit Net Income EBITDA EV
Vascular Biogenics (VBLT) 31,934 60,678 7,585 0 0 0 0 31,934
Actinium Pharmaceuticals (ATNM) 40,508 21,819 6,118 0 0 -23,165 -22,956 20,808
Bellerophon Therapeutics (BLPH) 42,722 20,578 9,116 0 0 5,289 3,488 25,522
Aclaris (ACRS) 210,933 217,239 80,009 19,616 9,434 -158,732 -152,933 125,340
AEterna Zentaris (AEZS) 48,829 25,011 23,104 0 0 0 0 45,328
Eyenovia (EYEN) 52,676 10,036 2,418 0 0 -21,770 -21,758 43,436
Zosano Pharma (ZSAN) 58,309 45,787 26,780 0 0 -37,102 -36,217 40,609
Celsion (CLSN) 38,224 43,587 24,755 500 0 -7,448 -6,903 42,211
Pernix Therapeutics Holdings (PTX) 12,702 274,770 447,052 69,680 19,178 -76,365 -44,352 352,585
Proteostasis Therapeutics (PTI) 48,033 105,749 23,764 0 0 -69,764 -68,376 -39,967
Leap Therapeutics (LPTX) 37,866 20,137 9,198 0 0 -22,121 -22,100 22,119
Aptevo Therapeutics (APVO) 39,687 66,127 39,928 26,552 4,550 -52,040 -49,681 30,790
Zafgen (ZFGN) 47,778 103,884 31,745 0 0 -54,878 -52,926 -25,741
Bio-Path (BPTH) 36,661 19,319 1,406 0 0 -8,958 -8,859 19,555
Sierra Oncology (SRRA) 43,319 84,175 13,704 0 0 -57,760 -57,561 -30,812
Innovate Biopharmaceuticals (INNT) 39,831 14,640 9,633 0 0 -12,714 -10,259 30,538
Alimera Sciences (ALIM) 29,110 50,242 53,924 49,996 44,932 -12,499 -4,567 55,209
DiaMedica Therapeutics (DMAC) 55,952 12,797 1,095 0 0 -5,721 -5,704 52,978
Vistagen Therapeutics (VTGN) 12,947 11,322 0 0 -26,585 -26,474 -8,051
Aerpio Pharmaceuticals (ARPO) 36,529 49,600 3,884 18,824 0 -11,158 -11,158 -11,628

Balance Sheet ($'000)2017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Cash23,80017,17114,20325,73735,37630,48123,24916,28421,70915,747
Accounts Receivable
Inventory
PP&E1591601482081231119820874161
Assets28,77922,72617,57929,06238,68634,40727,12619,07426,08320,137
Accounts Payable2,7933,0882,5982,6224,1304,7664,1493,5793,2985,325
Long-Term Debt
Liabilities4,6124,3755,99417,94522,55822,27220,4989,8999,0199,198
Stockholders' Equity24,16718,35111,58511,11716,12812,1356,6289,17517,06410,939
Income Statement ($'000)2017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Revenue
Cost of Revenue
Gross Profit
R&D6,4044,8816,8024,4164,2314,2346,4576,9086,7906,136
SG&A
Tax
Net Income-9,414-6,905-6,815-6,593-10,622-7,364-6,6321,480-8,603-8,366
Cash Flow ($'000)2017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-30
Cash Operating-2,357-6,369-5,478-6,053-7,452-7,050-6,868-7,183
Cash Investing20
Cash Financing017,89515,0051,008-67-4012,3221,260